logo
Biomedical waste treatment plant getting ready at Brahmapuram

Biomedical waste treatment plant getting ready at Brahmapuram

KOCHI: Kochi corporation's new initiative to address the growing problem of sanitary and special care waste disposal -- biomedical waste treatment plant -- is expected to be commissioned in September. The Rs 3.45-crore plant, a first-of-its-kind initiative by a local body in the state, is nearing completion at the Brahmapuram waste dumping site. All biomedical waste, except hospital-generated waste falling under the hazardous category, can be incinerated at the new plant.
On an average, around 100 tonnes of sanitary and special care waste are generated every month in Kochi, which includes sanitary napkins, diapers, and medical waste collected by government-approved agencies.
'Two government-approved agencies have currently collected more than two tonnes of sanitary and special care waste. This is being transported to the Kerala Enviro Infrastructure Ltd (KEIL) unit in Ambalamedu. Once the new plant is commissioned, we will be able to treat and dispose of the biomedical waste at Brahmapuram,' a senior health official with the Kochi corporation told TNIE.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Kidney racket: HC seeks report from state health officials
Kidney racket: HC seeks report from state health officials

Time of India

time35 minutes ago

  • Time of India

Kidney racket: HC seeks report from state health officials

Madurai: Madras high court on Tuesday directed the principal secretary of the health and family welfare department and the director of medical and rural health services to file a report on the action taken in connection with the kidney trafficking racket in the state. The court also sought a report from the authorities on the mechanism required to prevent organ theft and organ trading in the state. A division bench of justice S M Subramaniam and justice G Arul Murugan sought the report while hearing a public interest litigation filed by S N Sathishwaran of Ramanathapuram district. The petitioner sought to transfer the investigation to CBI for conducting a fair, impartial, and independent investigation and to take appropriate action against all people involved, irrespective of their political affiliation. The petitioner stated that kidney ailments were on the rise in the last few decades. Due to the advancement in medical technology, kidney transplants substantially increased over the years, particularly in several hospitals across the state. However, a few people were involved in illegalities, including kidney theft and medical irregularities in the transplant of kidneys.. He stated that it came to light that Dhanalakshmi Srinivasan Medical College and Hospital in Perambalur and Cethar Hospital in Trichy were found to have indulged in serious medical malpractice and kidney thefts. The petitioner alleged that both hospitals involved in the racket were connected to political personalities from DMK. The petitioner stated that the racket came to light when videos and testimonies surfaced online featuring workers from Pallipalayam and nearby areas in Namakkal, particularly from power loom and dyeing mill communities, claiming they were lured into selling kidneys for Rs 5 lakh to Rs 10 lakh. Several victims claimed they received much less than promised, even though the recipient paid Rs 10 lakh to the broker. People belonging to the economically weaker sections were abused, and their kidneys were removed. The petitioner also sought an interim direction to the state to constitute an independent, impartial, and competent committee headed by an IAS officer and medical professionals to probe the alleged illegal organ trade and related irregularities, including identification of victims, perpetrators, and institutions involved, and submit a detailed report to the court.

Stress got you sucking? The rise of adult pacifiers
Stress got you sucking? The rise of adult pacifiers

India Today

timean hour ago

  • India Today

Stress got you sucking? The rise of adult pacifiers

Stress. Burnout. Sleepless nights. For many adults, these aren't just buzzwords, they're daily realities. But now, some are turning to a surprising tool for relief: adult you read that CRIBS TO CUBICLES: THE PACIFIER COMEBACKWhat was once a baby essential is now making waves in adult lives. Silicone pacifiers—designed for grown-ups—are selling out across e-commerce Priced anywhere between Rs 80 and Rs 5,000 (or $1 and $70), they've become a go-to for those seeking relief from anxiety, insomnia, or even nicotine ARE PEOPLE USING THEM?Fans say they help calm the nerves, ease panic attacks, and promote better sleep. Some even claim pacifiers reduce the urge to smoke or snack, offering a sense of comfort that's oddly have a name for it: regression. Under stress, our brains sometimes seek out familiar, childhood comforts. The act of sucking, as associated with early emotional security, can trigger a calming response in the brain.A VIRAL CRAZE IN CHINAThe trend has exploded in China. On platforms like Weibo, videos featuring adult pacifier use have amassed billions of views. On Taobao, sellers report shipping thousands every month. It's become more than a product—it's a social phenomenon, complete with fan communities and viral Is It Safe? Not are ringing the alarm. Long-term pacifier use can lead to jaw strain, misaligned teeth, bite issues, and even airway obstruction, especially if used during while pacifiers may offer quick comfort, experts caution: they don't actually solve stress, they just mask ALTERNATIVES THAT ACTUALLY HELPIf you're looking to cope with stress, here are safer, expert-recommended options:Chewing gum (satisfies oral fixation without dental risk)Stress balls or fidget toolsMindfulness and meditationJournaling or expressive writingProfessional therapy or counsellingTHE BOTTOM LINEAdult pacifiers may feel comforting at the moment, but they're no long-term solution. Tackling stress takes more than silicone. It means facing the root cause, not just soothing the before you click 'add to cart,' ask yourself: do I need a pacifier or a real pause?- Ends

Lupin launches Bosentan tablets for oral suspension in US market
Lupin launches Bosentan tablets for oral suspension in US market

Business Standard

time4 hours ago

  • Business Standard

Lupin launches Bosentan tablets for oral suspension in US market

Lupin announced the launch of Bosentan tablets for oral suspension, 32 mg in the United States, following approval received by its alliance partner, NATCO Pharma, from the US Food and Drug Administration (USFDA). According to an exchange filing, NATCO holds exclusive first-to-file status for the product and will benefit from 180-day generic drug exclusivity. The product is the bioequivalent to Tracleer Tablets for Oral Suspension, marketed by Actelion Pharmaceuticals US, Inc. Bosentan is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in pediatric patients aged 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance (PVR), which is expected to result in an improvement in exercise ability. As per IQVIA MAT data for June 2025, Bosentan Tablets (RLD Tracleer) had estimated annual sales of approximately $10 million in the US market. Lupin is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. It specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Lupins consolidated net profit jumped 52.13% to Rs 1,219.03 crore on 11.78% increase in income from operations to Rs 6,163.75 crore in Q1 FY26 over Q1 FY25. Shares of Lupin declined 0.61% to Rs 1,956.50 on the BSE, while shares of Natco Pharma slipped 0.82% to Rs 885.95 on the BSE.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store